Citi raised the firm’s price target on Owens & Minor to $28 from $24 and keeps a Neutral rating on the shares. The analyst remains generally positive on the distributors heading into the Q1 reports, but cautions that this will be a difficult quarter from a comp perspective. Namely, GLP-1 growth will slow materially and the distributors will see limited benefit from commercial COVID vaccines, the analyst tells investors in a research note.